236 related articles for article (PubMed ID: 28819279)
61. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
62. Pathogenesis and management of essential thrombocythemia.
Beer PA; Green AR
Hematology Am Soc Hematol Educ Program; 2009; ():621-8. PubMed ID: 20008247
[TBL] [Abstract][Full Text] [Related]
63. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Hernández-Boluda JC; Pereira A; Gómez M; Boqué C; Ferrer-Marín F; Raya JM; García-Gutiérrez V; Kerguelen A; Xicoy B; Barba P; Martínez J; Luño E; Alvarez-Larrán A; Martínez-López J; Arbelo E; Besses C;
Haematologica; 2014 Apr; 99(4):e55-7. PubMed ID: 24488561
[No Abstract] [Full Text] [Related]
64. Proactive steps to optimize the management of polycythemia vera and myelofibrosis.
Mesa RA
Clin Adv Hematol Oncol; 2019 Sep; 17(9):475-477. PubMed ID: 31549966
[No Abstract] [Full Text] [Related]
65. [Myeloproliferative disorders].
Binder D; Fehr J
Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
[TBL] [Abstract][Full Text] [Related]
66. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
Boveri E; Passamonti F; Rumi E; Pietra D; Elena C; Arcaini L; Pascutto C; Castello A; Cazzola M; Magrini U; Lazzarino M
Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
[TBL] [Abstract][Full Text] [Related]
67. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
68. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
69. Capricious CALR mutated clones in myeloproliferative neoplasms.
Haslam K; Conneally E; Langabeer SE
Blood Cells Mol Dis; 2016 Mar; 57():110-1. PubMed ID: 26777583
[No Abstract] [Full Text] [Related]
70. The bone marrow in myeloproliferative and dysmyelopoietic syndromes.
Wolf BC; Neiman RS
Hematol Oncol Clin North Am; 1988 Dec; 2(4):669-94. PubMed ID: 3065324
[TBL] [Abstract][Full Text] [Related]
71. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
72. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
Rudzki Z; Sacha T; Stój A; Czekalska S; Wójcik M; Skotnicki AB; Grabowska B; Zduńczyk A; Okoń K; Stachura J
Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
[TBL] [Abstract][Full Text] [Related]
73. The disappearance of two alleles of JAK2 V617F from peripheral blood of a polycythaemia vera patient correlates with transformation into myelofibrosis.
Ashur-Fabian O; Amariglio N; Cohen Y; Nagler A; Rechavi G; Salomon O
Br J Haematol; 2007 Sep; 138(6):822-3. PubMed ID: 17760813
[No Abstract] [Full Text] [Related]
74. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Panova-Noeva M; Marchetti M; Russo L; Tartari CJ; Leuzzi A; Finazzi G; Rambaldi A; ten Cate H; Falanga A
Thromb Res; 2013 Jul; 132(1):88-93. PubMed ID: 23735588
[TBL] [Abstract][Full Text] [Related]
75. Assessing disease burden in patients with classic MPNs.
Geyer H; Mesa RA
Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
[TBL] [Abstract][Full Text] [Related]
76. Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.
Tiong IS; Casolari DA; Nguyen T; Van Velzen MJ; Ambler K; D'Andrea RJ; Ross DM
Blood Cancer J; 2016 Aug; 6(8):e459. PubMed ID: 27540717
[No Abstract] [Full Text] [Related]
77. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
[TBL] [Abstract][Full Text] [Related]
78. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F; Giorgino T; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Caramazza D; Merli M; Pietra D; Casalone R; Rotunno G; Barbui T; Cazzola M; Vannucchi AM
Leukemia; 2017 Dec; 31(12):2726-2731. PubMed ID: 28561069
[TBL] [Abstract][Full Text] [Related]
79. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
Michiels JJ
Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
[TBL] [Abstract][Full Text] [Related]
80. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Mesa RA; Tefferi A
Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
